{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:21:11Z","timestamp":1791580871230,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106668","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T06:48:10Z","timestamp":1754635690000},"page":"106668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy of alternative vs. standard dosing strategies of anti-CD20 monoclonal antibodies in multiple sclerosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-0329","authenticated-orcid":false,"given":"Ida","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahryar","family":"Rajai Firouzabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepehr","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Aarabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateme","family":"Mohammadifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin","family":"Sadraei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Alinejadfard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Etemadifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehri","family":"Salari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.msard.2025.106668_bib0001","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.blre.2013.07.002","article-title":"Anti-CD20 monoclonal antibodies: beyond B-cells","volume":"27","author":"Avivi","year":"2013","journal-title":"Blood Rev."},{"issue":"7","key":"10.1016\/j.msard.2025.106668_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw. Open"},{"issue":"20","key":"10.1016\/j.msard.2025.106668_bib0003","doi-asserted-by":"crossref","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the mirror study","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106668_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102704","article-title":"Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness","volume":"48","author":"Barun","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106668_bib0005","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00415-023-12084-4","article-title":"COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients","volume":"271","author":"Bisecco","year":"2024","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106668_bib0006","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jrsm.1458","article-title":"The effect direction plot revisited: application of the 2019 cochrane handbook guidance on alternative synthesis methods","volume":"12","author":"Boon","year":"2021","journal-title":"Res. Synth. Methods"},{"issue":"6","key":"10.1016\/j.msard.2025.106668_bib0007","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00415-021-10399-8","article-title":"Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis","volume":"268","author":"Boremalm","year":"2021","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106668_bib0008","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585231208311","article-title":"Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity","volume":"30","author":"Bou Rjeily","year":"2024","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2025.106668_bib0009","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs,"},{"issue":"3","key":"10.1016\/j.msard.2025.106668_bib0010","first-page":"235","article-title":"Targeting CD20 in multiple sclerosis\u2014Review of current treatment strategies","volume":"57","author":"Chmielewska","year":"2023","journal-title":"Neurol. Neurochir. Pol."},{"issue":"5","key":"10.1016\/j.msard.2025.106668_bib0011","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200152","article-title":"Efficacy of rituximab outlasts b-cell repopulation in multiple sclerosis: time to rethink dosing?","volume":"10","author":"Claverie","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2025.106668_bib0012","article-title":"Sustained low relapse rate with highly variable b-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis","volume":"10","author":"Cucuzza","year":"2023","journal-title":"Neurol.: Neuroimmunol. NeuroInflamm."},{"key":"10.1016\/j.msard.2025.106668_bib0013","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14-2023","author":"de S\u00e8ze","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.msard.2025.106668_bib0014","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1177\/1352458520952036","article-title":"De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis","volume":"27","author":"Disanto","year":"2021","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2025.106668_bib0015","first-page":"e405","article-title":"B-cell\u2013targeted therapies in relapsing forms of MS","volume":"4","author":"Dubey","year":"2017","journal-title":"Neurol.: Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106668_bib0016","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients","volume":"15-2024","author":"Elgenidy","year":"2024","journal-title":"Front Neurol."},{"key":"10.1016\/j.msard.2025.106668_bib0017","article-title":"Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy","volume":"73","author":"Gadani","year":"2021","journal-title":"EBio Medicine"},{"key":"10.1016\/j.msard.2025.106668_bib0018","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-025-08098-7","article-title":"Clinical and radiological activity after extended interval and standard interval dosing of ocrelizumab in multiple sclerosis: a systematic review and meta-analysis","author":"Ghajarzadeh","year":"2025","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2025.106668_bib0019","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40893-017-0022-6","article-title":"Pediatric versus adult MS: similar or different?","volume":"2","author":"Ghezzi","year":"2017","journal-title":"Mult. Scler. Demyelinating. Disord."},{"issue":"9","key":"10.1016\/j.msard.2025.106668_bib0020","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1111\/ene.15891","article-title":"Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience","volume":"30","author":"Guerrieri","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106668_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103798","article-title":"Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab","volume":"62","author":"Habek","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106668_bib0022","doi-asserted-by":"crossref","first-page":"e1230","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell. Syst. Rev."},{"key":"10.1016\/j.msard.2025.106668_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101468","article-title":"Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity","volume":"37","author":"Juto","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106668_bib0024","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12969-019-0365-y","article-title":"Rituximab-associated hypogammaglobulinemia in pediatric patients with autoimmune diseases","volume":"17","author":"Khojah","year":"2019","journal-title":"Pediatr. Rheumatol. Online J."},{"issue":"2","key":"10.1016\/j.msard.2025.106668_bib0025","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106668_bib0026","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2025.106668_bib0027","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","article-title":"Anti-CD20 therapies for multiple sclerosis: current status and future perspectives","volume":"269","author":"Margoni","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106668_bib0028","article-title":"Risk-of-bias visualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","author":"McGuinness","year":"2020","journal-title":"Res. Synth. Methods"},{"issue":"7","key":"10.1016\/j.msard.2025.106668_bib0029","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/13524585241250199","article-title":"Memory B cell-guided extended interval dosing of ocrelizumab in multiple sclerosis","volume":"30","author":"Meng","year":"2024","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2025.106668_bib0030","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bjh.15132","article-title":"New insights in type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies","volume":"180","author":"Meyer","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.msard.2025.106668_bib0031","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.msard.2025.106668_bib0032","article-title":"Clinical and immunological impact of ocrelizumab extended interval dosing in multiple sclerosis: a single-center","volume":"25","author":"Nasello","year":"2024","journal-title":"Real-World Exp.. Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.msard.2025.106668_bib0033","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/13524585241245296","article-title":"Extended interval dosing with ocrelizumab in multiple sclerosis","volume":"30","author":"Novak","year":"2024","journal-title":"Mult. Scler. J.l"},{"key":"10.1016\/j.msard.2025.106668_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102988","article-title":"Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases","volume":"52","author":"Oksbjerg","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106668_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int. J. Surg."},{"issue":"2","key":"10.1016\/j.msard.2025.106668_bib0036","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s13760-024-02480-6","article-title":"Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis","volume":"124","author":"Rabea","year":"2024","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.msard.2025.106668_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105028","article-title":"Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing - similar clinical efficacy with decreased immunoglobulin M deficiency rates","volume":"79","author":"Rempe","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106668_bib0039","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12974-023-02900-z","article-title":"Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis","volume":"20","author":"Rodriguez-Mogeda","year":"2023","journal-title":"J. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2025.106668_bib0040","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106668_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103287","article-title":"Clinical impact of ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19(+)B-cell repopulation","volume":"56","author":"Sahi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2025.106668_bib0042","first-page":"1354","article-title":"Economic burden of multiple sclerosis in the United States: a systematic literature review","volume":"29","author":"Schauf","year":"2023","journal-title":"J. Manage Care Spec. Pharm."},{"issue":"6","key":"10.1016\/j.msard.2025.106668_bib0043","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.medj.2023.05.001","article-title":"Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis","volume":"4","author":"Schuckmann","year":"2023","journal-title":"Medical"},{"issue":"6","key":"10.1016\/j.msard.2025.106668_bib0044","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200021","article-title":"Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 and other risk factors associated with COVID-19 severity","volume":"9","author":"Simpson-Yap","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106668_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106191","article-title":"Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: a multicentre study","volume":"93","author":"Smolik","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106668_bib0046","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"ROB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2025.106668_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117501","article-title":"Personalizing ocrelizumab treatment in multiple sclerosis: what can we learn from Sars-Cov2 pandemic?","volume":"427","author":"Tazza","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2025.106668_bib0048","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.msard.2025.106668_bib0049","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.msard.2025.106668_bib0050","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/13524585211028833","article-title":"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic","volume":"28","author":"van Lierop","year":"2022","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2025.106668_bib0051","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/13524585231223069","article-title":"Control of disease activity with large extended-interval dosing of rituximab\/ocrelizumab in highly active pediatric multiple sclerosis","volume":"30","author":"Venet","year":"2024","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2025.106668_bib0052","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/bloodadvances.2021004629","article-title":"Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients","volume":"5","author":"Vijenthira","year":"2021","journal-title":"Blood Adv."},{"issue":"14","key":"10.1016\/j.msard.2025.106668_bib0053","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106668_bib0054","series-title":"The Newcastle-Ottawa Scale (NOS) For Assessing the Quality of Nonrandomised Studies in Meta-Analyses","author":"Wells","year":"2000"},{"issue":"8","key":"10.1016\/j.msard.2025.106668_bib0055","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2025.106668_bib0056","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13311-022-01289-6","article-title":"Is it time for ocrelizumab extended interval dosing in relapsing remitting MS? evidence from an Italian multicenter experience during the COVID-19 pandemic","volume":"19","author":"Zangh\u00ec","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.msard.2025.106668_bib0057","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1570159X22666231002142709","article-title":"ocrelizumab extended interval dosing in primary progressive multiple sclerosis: an Italian experience","volume":"22","author":"Zangh\u00ec","year":"2024","journal-title":"Curr. Neuropharmacol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:15:59Z","timestamp":1774998959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":56,"alternative-id":["S2211034825004109"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106668","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of alternative vs. standard dosing strategies of anti-CD20 monoclonal antibodies in multiple sclerosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106668"}}